基本情况：
湖南大学，生命医学交叉研究院，副教授，博士生导师。2011年于华南师范大学获得生物物理学博士学位，并于同年赴美国纽约大学医学院细胞生物学系进行博士后研究。2013年起在明尼苏达大学荷美尔医学研究所任荷美尔研究员，2015年受聘于湖南大学生物学院&生命医学交叉研究院，现为副教授，博士生导师。主要研究方向为肿瘤遗传的分子机制及靶向治疗新方法的探索，近年来一直关注于细胞死亡、自噬和免疫的关系，及其在肿瘤治疗中的应用。作为独立PI开展工作以来，详细阐述了突变体p53促进结直肠癌发生发展的获得性功能（GOF）及产生抗药性的机理，同时鉴定出两种全新的结直肠癌生物标志物PUMA和SIRT6。主持国家自然科学基金1项，湖南省重大研发计划子课题1项，湖南省自然科学基金1项，深圳市科创委基础研究项目1项。以通讯作者在Inter. J. Bio. Sci, Theranostics, Materials Today Bio, Cell Death & Dis等多个著名国际期刊上发表论文17篇，他引总次数超过1000。主讲课程《细胞工程》入选湖南省一流本科课程，荣获2019年湖南省高校教师课堂教学竞赛二等奖，2018年湖南大学讲课比赛一等奖。Tel：18673177768；E-mail：yingjiezhang@hnu.edu.cn
教育和培训经历：
2006-2011 华南师范大学生物光子学研究院，生物物理专业，博士
2011-2013 纽约大学医学院，细胞生物学系，博士后
工作经历：
2013-2015 明尼苏达大学，荷美尔医学研究所
2015-至今 湖南大学，生物学院&生命医学交叉研究院
学术兼职：
中国抗癌协会会员
中国遗传学会会员
中国生物化学学会会员
研究领域：
1. 肿瘤遗传，免疫及转化医学；
2. 细胞死亡自噬及免疫的分子机制和信号转导通路；
3. 鉴定新的肿瘤生物标志物，治疗靶点并进行药物筛选；
4. 利用新型纳米/高分子材料进行肿瘤的原位靶向治疗。
主持项目：
1. 湖南省重大研发计划子课题，2020DK2001，高稳定性转基因小鼠肿瘤模型构建的关键技术研发，2020/01-2022/12，10万元，在研，主持
2. 湖南省自然科学基金面上项目，2020JJ4182，突变体p53的获得性功能及其在淋巴瘤中的应用研究，2020/01-2022/12，5万元，在研，主持
3. 国家自然科学基金青年项目，31801140，PUMA调控自噬的分子机制及其在结直肠癌中的功能研究，2019/01-2021/12，26万元，在研，主持
4. 深圳市科创委基础研究项目，JCYJ20160530192802733，PUMA在肿瘤自噬中的功能和分子机制研究，2017/03-2019/02，30万元，已结题，主持
5. 中央高校基础科研项目，531107040909，靶向Akt治疗结直肠癌分子机制的研究，2015/09-2019/08，20万元，已结题，主持
发表论文：
1. Nannan Liu, Xinxiu Jiang, Leiming Guo, Chuchu Zhang, Meimei Jiang, Zhuoran Sun, Yizheng Zhang, Wunan Mi, Jiehan Li, Yang Fu, Feng Wang, Lingling Zhang* and Yingjie Zhang*. “Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway”. International Journal of Biological Sciences 2022; 18(6): 2419-2438. doi: 10.7150/ijbs.67200. (IF: 10.75)
2. Jiehan Li, Guang Luo, Chuchu Zhang, Shuaiyu Long, Leiming Guo, Ge Yang, Feng Wang, Lingling Zhang, Liyang Shi*, Yang Fu* and Yingjie Zhang*. “In situ Injectable Hydrogel-loaded Drugs Induce Anti-tumor Immune Responses in Melanoma Immunochemotherapy”. Materials Today Bio 2022; doi:10.1016/j.mtbio.2022.100238. (IF: 10.761)
3. Yizheng Zhang,Chuchu Zhang,Jiehan Li,Meimei Jiang,Shuning Guo,Ge Yang,Lingling Zhang*,Feng Wang,Shiqi Yi,Jiangang Wang,Yang Fu*, Yingjie Zhang*.“Inhibition of AKT induce p53/SIRT6/PARP1-dependent parthanatos to suppress tumor growth”. Cell Communication and Signaling 2022; Doi:10.1186/s12964-022-00897-1. (IF: 7.525)
4. Tingting Hu, Yingjie Zhang, Tianqing Yang, Qingnan He, Mingyi Zhao. “LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia”. Frontiers in Genetics 2022; doi: 10.3389/fgene.2022.795820. eCollection 2022. (IF: 4.772)
5. Wunan Mi, Chuyue Wang, Guang Luo, Jiehan Li, Yizheng Zhang, Meimei Jiang, Chuchu Zhang, Nannan Liu, Xinxiu Jiang, Ge Yang, Lingling Zhang, Ge Zhang, Yang Fu*, Yingjie Zhang*, Yang Fu*. “Targeting ERK induced cell death and p53/ROS-dependent protective autophagy in colorectal cancer”. Cell Death Discovery. 2021; 7: 375. doi: 10.1038/s41420-021-00677-9. (IF: 7.109)
6. Huanan Wang, Yeying Liu, Jie Ding, Yuan Huang, Jing Liu, Nannan Liu, Yue Ao, Yi Hong, Lefeng Wang, Lingling Zhang, Jiangang Wang and Yingjie Zhang*. “Targeting mTOR suppressed colon cancer growth through 4EBP1/eIF-4E/PUMA pathway”. Cancer Gene Therapy 2020; doi: 10.1038/s41417-019-0117-7. (IF: 5.854)
7. Jing Liu, Shuaiyu Long, Huanan Wang, Nannan Liu, Chuchu Zhang, Lingling Zhang and Yingjie Zhang*. “Blocking AMPK/ULK1‑dependent autophagy promoted apoptosis and suppressed colon cancer growth”. Cancer Cell International 2019; 19: 336. doi: 10.1186/s12935-019-1054-0. (IF: 6.429)
8. Yuan Huang, Nannan Liu, Jing Liu, Yeying Liu, Chuchu Zhang, Shuaiyu Long, Guang Luo, Lingling Zhang and Yingjie Zhang*. “Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA”. Cell Cycle 2019; 14: 1-14. (IF: 5.173)
9. Yeying Liu, Yuan Huang, Jie Ding, Nannan Liu, Shuang Peng, Jiangang Wang, Feng Wang and Yingjie Zhang*. “Targeting Akt by SC66 triggers GSK-3β mediated apoptosis in colon cancer therapy”. Cancer Cell International 2019; 9(19): 124. (IF: 6.429)
10. Yingjie Zhang, Liming Nie, Keqian Xu, Yang Fu, Juchang Zhong, Kongzhen, Gu, Lingling Zhang. “SIRT6, A Novel Direct Transcriptional Target of FoxO3a, Mediates Colon Cancer Therapy”. Theranostics 2019; 9(8) 2380-2394. (IF: 11.6)
11. Jingfei Chen, Juchang Zhong, Yeying Liu, Yuan Huang, Fei Luo, Yingjun Zhou, Xi Pan, Shousong, Cao, Lingling Zhang, Yingjie Zhang*, Jiangang Wang*. “Purified vitexin compound 1, a new neolignan isolated compound, promotes PUMA-dependent apoptosis in colorectal cancer”. Cancer Medicine 2018; 7(12): 6158-6169. (IF: 4.711)
12. Juchang Zhong#, Yingjie Zhang#, Jingfei Chen, Ruiying Huang, Yikun Yang, Haoxiang Chen, Yuan Huang, Weihong Tan, and Zhikai Tan. “In Vitro Study of Colon Cancer Cell Migration Using E-Jet 3D Printed Cell Culture Platforms”. Macromol Biosci 2018; 18(11): e1800205. (IF: 5.859)
13. Li Sun, Yuan Huang, Yeying Liu, Yujie Zhao, Xiaoxiao He, Lingling Zhang, Feng Wang and Yingjie Zhang*. “Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis”. Cell Death & Disease 2018; 9(9): 911. (IF: 9.685)
14. Xianwang Wang, Xiaochun Peng, Xueqing Zhang, Hanyi Xu, Chengbiao Lu, Lian Liu, Jiaxing Song, Yingjie Zhang*. “The Emerging Roles of CIB1 in Cancer”. Cell Physi Biochemi 2017; 43: 1413-1424.
15. Zhikai Tan, Yikun Yang, Shurui Liao, Juchang Zhong, Yingjie Zhang*, Weihong Tan. “3D printed scaffolds for tumor targeting and controlled drug release”. J Controlled Release 2017; 259: e5-e195. (IF: 11.467)
16. Lingling Zhang, Huanan Wang, Wei Li, Juchang Zhong, Rongcheng Yu, Xinfeng Huang, Honghui Wang, Zhikai Tan, Jiangang Wang, Yingjie Zhang*. “Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis”. Oncotarget 2017; 8(2): 3289-3303.
17. Li Sun, Defeng Wang, Xiaotian Li, Lingling Zhang, Hui Zhang, Yingjie Zhang*. “Extracellular matrix protein ITGBL1 promotes ovarian cancer cell migration and adhesion through Wnt/PCP signaling and FAK/SRC pathway”. BIOMED PHARMACOTHER 2016; 81: 145-151. (IF: 7.419)
18. Lei Wang, Ji Wang, Hua Xiong, Fengxia Wu, Tian Lan, Yingjie Zhang, Xiaolan Guo, Huanan Wang, Mohammad Saleem, Cheng Jiang, Junxuan Lu, Yibin Deng. “Co-Targeting Hexokinase 2-Mediated Warburg Effect and ULK1-Dependent Autophagy Suppresses Tumor Growth of PTEN- and TP53-Deficiency-Driven Castration-Resistant Prostate Cancer”. EBioMedicine 2016; 7: 50-61. (IF: 11.205)
19. Huanan Wang, Lei Wang, Yingjie Zhang, Ji Wang, Yibin Deng, Degui Lin. “Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth” Cancer Cell Int. 2016; 16(16): 9. (IF: 6.429)
20. Huanan Wang, Lingling Zhang, Xu Yang, Yipeng Jin, Shimin Pei, Di Zhang, Yingjie Zhang* and Degui Lin*. “PUMA Mediates the Combinational Therapy of 5-FU and NVP-BEZ235 in Colon Cancer” Oncotarget 2015; 6(16): 14385-98.
21. Lei Wang, Hua Xiong, Fengxia Wu, Yingjie Zhang, Ji Wang, Liyan Zhao, Xiaolan Guo, Li-Ju Chang, Yong Zhang, M. James You, Shahriar Koochekpour, Mohammad Saleem, Haojie Huang, Junxuan Lu and Yibin Deng. “Hexokinase 2-Mediated Warburg Effect Is Required for PTEN and p53 Deficiency-Driven Prostate Cancer Growth”. Cell Rep 2014; 8: 1-14. (IF: 9.995)
22. Jie Feng, Yingjie Zhang and Da Xing. “Low-power laser irradiation (LPLI) promotes VEGF expression and vascular endothelial cell proliferation through the activation of ERK/Sp1 pathway”. Cellular Signalling. 2012; 24: 1116-1125. (IF: 4.85)
23. Yingjie Zhang and Da Xing. “PUMA Promotes Bax Activation in a FOXO3a-dependent Manner in STS-induced Apoptosis”. J Innov Opt Health Sci 2010; 3: 31-38. (IF: 2.396)
24. Lingling Zhang, Yingjie Zhang and Da Xing. “LPLI Inhibits Apoptosis Upstream of Bax Translocation via a GSK-3β-Inactivation Mechanism”. J. Cell. Physiol. 2010; 224(1): 218-228 (Cover Story). (IF: 6.513)
25. Yingjie Zhang, Da Xing and Lei Liu. “PUMA promotes Bax translocation by both directly interacting with Bax and by competitive binding to Bcl-XL during UV-induced apoptosis”. Mol. Biol. Cell. 2009; 20: 3077-3087. (IF: 3.612)
26. Yingjie Zhang, Da Xing and Lei Liu. “The molecular imaging study of PUMA and Bcl-2 family members in UV-induced apoptosis”. Chinese Journal of Lasers 2009; 36 (10): 2609-2613.
27. Yingjie Zhang* and Qun Chen. “PUMA Promotes Bax Translocation in FOXO3a-dependent Pathway during STS-induced Apoptosis”. Proc. of SPIE. 2009; 7519: 75191A1-9.
28. Lei Liu, Yingjie Zhang and Xianwang Wang. “Using FRET Technique to Investigate The Apoptotic Mechanism Induced by Cisplatin in Living Cells”. Progress in Biochemistry and Biophysics 2009; 36 (9): 1172-1179
29. Lei Liu, Yingjie Zhang and Xianwang Wang. “Involvement of Caspase-dependent and –independent apoptotic pathways in cisplatin-induced apoptosis”. Proc. of SPIE. 2009; 7178: 71780N1-8.
30. Yingjie Zhang, Da Xing, Yinyuan Wu and Lei Liu. “PUMA promotes Bax translocation by competitive binding to Bcl-Xl during UV-induced apoptosis”. Proc. of SPIE. 2008; 6857:
奖励与荣誉：
1. 主讲课程《细胞工程》入选2019年湖南省一流课程
2. 湖南省2019年普通高校教师课堂教学竞赛二等奖
3. 湖南大学2018年讲课比赛一等奖
4. 湖南大学2018年本科毕业设计（论文）优秀指导教师
5. 2016年度深圳市科技项目奖先进个人
